ArticleAnnals of surgical oncology2026
Long-Term Outcomes of Minimally Invasive Total Gastrectomy for Locally Advanced Gastric Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe oncologic safety of minimally invasive total gastrectomy (MITG) compared with open total gastrectomy (OTG) for locally advanced gastric cancer remains unclear. This study aimed to evaluate the long-term oncologic outcomes of MITG compared with OTG for locally advanced gastric cancer.
methodsFrom 2007 to 2019, 1319 OTG and 348 MITG patients with locally advanced gastric cancer were retrospectively analyzed. The long-term oncologic outcomes of MITG and OTG were compared using propensity score-matching (PSM).
resultsAfter PSM, clinicopathologic features were well-balanced. The MITG procedure showed less blood loss but a longer operative time. The rates of complications classified as Clavien-Dindo grade ≥III were comparable in the two groups (OTG 12.4% vs. MITG 10.6%; P = 0.470), including anastomotic leakage (OTG 2.9% vs. MITG 4.7%; P = 0.230). The 5 year overall survival rate was 83.0% in the OTG group (95% confidence interval [CI], 78.4-86.7%) and 87.3% in the MITG group (95% CI, 83.2-90.5%) (P = 0.398). The hazard ratio (HR) for death in the MITG group compared with the OTG group was 0.88 (95% CI, 0.61-1.27; P = 0.505). The 5-year relapse-free survival was 71.0% in the OTG group (95% CI, 64.8-76.4%) and 72.5% in the MITG group (95% CI, 66.6-77.5%) (P = 0.895). The HR for recurrence in the MITG group compared with the OTG group was 1.08 (95% CI, 0.80-1.46; P = 0.633).
conclusionFor locally advanced gastric cancer, MITG demonstrated long-term oncologic outcomes similar to those of OTG. Therefore, MITG could be an oncologically safe option for locally advanced gastric cancer, although randomized studies are needed to confirm this finding.
Indexed as
Identifiers
41555131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.